Addition of New Automated Strut System Further Solidifies
Company’s Commitment to Medtech Innovation
WEST CHESTER, PA – December 1, 2021 – Today, the Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes**, acting through its affiliate, Synthes GmbH, has acquired the Israeli company, OrthoSpin, Ltd. OrthoSpin developed and manufactures a first-of-its kind technology – an automated strut system – which is used in conjunction with DePuy Synthes MAXFRAME™ Multi-Axial Correction System, an external ring fixation system. This acquisition is a clear example of Johnson & Johnson’s continued commitment to advancing innovation in the medtech space.
Ring fixation systems are a common treatment for correcting complex bone deformities, bone lengthening, setting complex fractures, and addressing issues such as nonunion. Currently, treatment necessitates manual strut adjustments by patients and caregivers daily. With this cutting-edge technology, strut adjustments are automated and may enhance the patient experience, potentially reducing the risk of negative clinical outcomes caused by unintended strut adjustment errors.
Deformity correction with ring fixation plays an important role in orthopaedics. DePuy Synthes has been committed to this area with the introduction of the MAXFRAME™ System in 2017, and most recently with the launch of new frame innovations and planned next generation software. With the addition of the OrthoSpin technology, DePuy Synthes is better positioned to serve healthcare professionals and patients who benefit from these critical advancements during the complex post-surgery recovery period.
“DePuy Synthes is deeply committed to patients who are in need of deformity correction surgery,” said Oray Boston***, Worldwide President, DePuy Synthes Trauma, Extremities, Craniomaxillofacial and Animal Health. “The acquisition of OrthoSpin clearly demonstrates our strong desire to help these patients navigate their recovery with more confidence and less uncertainty with their strut adjustments. It also demonstrates our commitment to bringing transformative Medtech advancements to the industry through the application of automated technology that addresses a wide range of orthopaedic challenges.”
Johnson & Johnson Innovation – JJDC, Inc. led the Series A financing of OrthoSpin in July 2018 and also led the Series B financing in March 2020. Earlier this year, OrthoSpin received 510(k) clearance from the U.S. Food and Drug Administration for its second generation, automated, digitally enabled external fixation system for orthopaedic treatments, the OrthoSpin G2 System, which is also licensed as a medical device (AMAR) in Israel.
Since its initial release, the OrthoSpin system has been used in numerous surgical procedures with positive feedback from surgeons and patients. Now that the acquisition is complete, DePuy Synthes will integrate the company and develop a robust supply chain before making the product widely available in the near future.
About Johnson & Johnson Medical Devices Companies
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
About DePuy Synthes
DePuy Synthes, the Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopaedics portfolios in the world that helps heal and restore movement for the millions of patients we serve. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery and sports medicine, in addition to the VELYS™ Digital Surgery portfolio, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide.
Building on our proud product innovation and legacy of industry firsts, we are reimagining the orthopaedic landscape with new advancements in medical technologies and digital surgery across the entire continuum of care to Keep People Moving today and tomorrow. For more information, visit www.depuysynthes.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the acquisition of OrthoSpin, Ltd. and development of OrthoSpin’s automated strut system. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Synthes GmbH, DePuy Synthes and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges related to integrating the products and operations of OrthoSpin, as well as the ability to ensure continued performance or market growth of OrthoSpin’s products; the potential that the expected benefits and opportunities related to the transaction may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Synthes GmbH, DePuy Synthes and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.
*Comprising the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment
**DePuy Synthes represents the products and services of DePuy Synthes Sales, Inc. and its affiliates.
***Oray Boston is an employee of Medical Device Business Services, Inc.
©DePuy Synthes 2021. All rights reserved.
Please refer to the instructions for use for a complete list of indications, contraindications, warnings and precautions.